anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is unclear whether normal human skin tissue or abnormal scarring are photoreceptive. Therefore, this study investigated photosensitivity in normal skin tissue and hypertrophic scars. The expression of opsins, which are photoreceptor proteins, in normal dermal fibroblasts (NDFs) and hypertrophic scar fibroblasts (HSFs) was examined. After exposure to blue light (BL), changes in the expression levels of αSMA and clock-related genes, specifically PER2 and BMAL1, were examined in both fibroblast types. Opsins were expressed in both fibroblast types, with OPN3 exhibiting the highest expression levels. After peripheral circadian rhythm disruption, BL induced rhythm formation in NDFs. In contrast, although HSFs showed changes in clock-related gene expression levels, no distinct rhythm formation was observed. The expression level of αSMA was significantly higher in HSFs and decreased to the same level as that in NDFs upon BL exposure. When OPN3 knocked-down HSFs were exposed to BL, the reduction in αSMA expression was inhibited. This study showed that BL exposure directly triggers peripheral circadian synchronization in NDFs but not in HSFs. OPN3-mediated BL exposure inhibited HSFs. Although the current results did not elucidate the relationship between peripheral circadian rhythms and hypertrophic scars, they show that BL can be applied for the prevention and treatment of hypertrophic scars and keloids.
Standard diabetes education will be given to individuals with diabetes in this group. This training will last for 3 months, once in 10 days. A total of 9 interviews will be provided.
The present invention relates to a composition for a systemic lupus erythematosus risk prediction. In detail, in case where copy number variants of 1q25.1, C4 and 10q21.3 loci occur, the variants are regarded as high-risk groups for a systemic lupus erythematosus through the composition. The composition of the present invention enables prediction for the risk of systemic lupus erythematosus as the copy number variants of the three loci have a synergy effect for a development of systemic lupus erythematosus. Furthermore, the present invention is a test-friendly method which reduces analytical errors which may be created due to a new equipment purchased or technological limitations as a PCR generally implemented in a inspection room of majority of hospitals is used. In addition, the present invention is able to apply a non-invasive method to a person to be tested. Ultimately, the present invention predicts the risk of systemic lupus erythematosus which will essentially contribute to delaying development of the disease or to preventing an aggravation of state.
Plant recognition of pathogen-associated molecular patterns (PAMPs) is pivotal in triggering immune responses, highlighting their potential as inducers of plant immunity. However, the number of PAMPs identified and applied in such contexts remains limited. In this study, we characterize a novel PAMP, designated Ss4368, which is derived from Scleromitrula shiraiana. Ss4368 is specifically distributed among a few fungal genera, including Botrytis, Monilinia, and Botryotinia. The transient expression of Ss4368 elicits cell death in a range of plant species. The signaling peptides, three conserved motifs, and cysteine residues (C46, C88, C112, C130, and C148) within Ss4368 are crucial for inducing robust cell death. Additionally, these signaling peptides are essential for the protein's localization to the apoplast. The cell death induced by Ss4368 and its homologous protein, Bc4368, is independent of the SUPPRESSOR OF BIR1-1 (SOBIR1), BRI1-ASSOCIATED KINASE-1 (BAK1), and salicylic acid (SA) pathways. Furthermore, the immune responses triggered by Ss4368 and Bc4368 significantly enhance the resistance of Nicotiana benthamiana to Phytophthora capsici. Therefore, we propose that Ss4368, as a novel PAMP, holds the potential for developing strategies to enhance plant resistance against P. capsici.
The invention relates to a foot bath traditional Chinese medicine composition for removing beriberi. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20-30 parts of golden cypress, 10-20 parts of goldthread root, 10-20 parts of sophora flower (fried), 15 parts of alum, 10-15 parts of Chinese lobelia, 20-30 parts of dried orange peel, 10-20 parts of pseudolarix, 20-25 parts of sophora flavescens, 15 parts of liquorice (fried), 5-15 parts of rhizoma atractylodis (fried), 5-15 parts of paulownia root with vinegar and 10-20 parts of blackgrass with wine. The foot bath lotion is used by foot bath, and can relieve tension, eliminate dampness and astringe sweat, dispel wind and remove dampness, promote blood circulation and remove meridian obstruction, moisten skin and promote granulation, astringe and relieve pain, promote eruption and kill parasites to relieve itching. Has obvious special curative effect on beriberi, tinea pedis, sweaty feet and eczema. Moreover, by the heat effect of foot bath, the effective components in the medicine can clean the surface skin, dissolve the skin cutin and adjust the yin-yang balance of each viscera of the whole body. Thereby achieving the purposes of treating internal diseases by external therapy and treating upper diseases by lower therapy, and having obvious curative effect, safety, reliability, convenient use and high cure rate.
1. Technical Result Increase in stability and reduction of toxicity.         2. Essence A method comprises reacting in organic medium of alkylsilylated derivatives e.g. trimethylsilyl chloride or trimethylchlorosilane with an alkaline iodide such as sodium iodide in the presence of water, whereafter hydroiodic acid is formed in situ, reacting hydroiodic acid with oil fatty acid ester, in particular oil fatty acid methyl ester obtained from rapeseed.     3. Field of Application Medicine, in particular for goiter treatment.
BACKGROUND: There has been a growing body of research focusing on patients with Congestive Heart Failure (CHF) and chronic obstructive pulmonary disease (COPD) admitted to the intensive care unit (ICU). However, the optimal blood pressure (BP) level for such patients remains insufficiently explored. This study aimed to investigate the associations between systolic blood pressure (SBP) and in-hospital mortality among ICU patients with both CHF and COPD.
METHODS: This retrospective cohort study enrolled 6309 patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. SBP was examined as both a continuous and categorical variable, with the primary outcome being in-hospital mortality. The investigation involved multivariable logistic regression, restricted cubic spline regression, and subgroup analysis to determine the relationship between SBP and mortality.
RESULTS: The cohort consisted of 6309 patients with concurrent CHF and COPD (3246 females and 3063 males), with an average age of 73.0 ± 12.5 years. The multivariate analysis revealed an inverse association between SBP and in-hospital mortality, both as a continuous variable (odds ratio = 0.99 [95% CI, 0.99~1]) and as a categorical variable (divided into quintiles). Restricted cubic spline analysis demonstrated an L-shaped relationship between SBP and mortality risk (P nonlinearity < 0.001), with an inflection point at 99.479 mmHg. Stratified analyses further supported the robustness of this correlation.
CONCLUSION: The relationship between SBP and in-hospital mortality in patients with both CHF and COPD follows an L-shaped pattern, with an inflection point at approximately 99.479 mmHg.
PURPOSE: An antibiotics peptide is provided to ensure strong and simple constitution and to use as a template for generating useful antibiotics. CONSTITUTION: An antibiotics peptide has an amino acid sequence of sequence number 1 or 2. A pharmaceutical composition contains the antibiotics peptide as an active ingredient. An antibacterial composition against microorganism contains an antibacterial peptide as an active ingredient. The microorganism is gram positive bacteria. The gram positive bacteria is Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermis or Micrococcus luteus.
Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
Short-term continuous subcutaneous insulin infusion will be adminstrated to maintained euglycemia for 1 week，Then subsequent therapy using basal insulin plus metformin will be administrated. After withdrawal of the medicine, wearable devices and smart apps will be used for long-term management.
Women with the Metabolic Syndrome (central obesity, insulin resistance, and dyslipidemia) are at especially high risk for coronary heart disease (CHD). The prevalence of the Metabolic Syndrome increases with menopause and may partially explain the acceleration in CHD after menopause. Menopause is associated with increased central adiposity, insulin resistance, dyslipidemia (hypertriglyceridemia, increased low density lipoprotein (LDL), reduced high density lipoprotein (HDL) and small dense LDL particles), and increased thrombotic/inflammatory states, but there are no studies investigating the mechanisms that mediate these changes. The objectives of the proposed project are to investigate the emergence of the features of the Metabolic Syndrome in women followed prospectively through the menopause and determine if these features can be reversed with transdermal estrogen. We hypothesize that the increase in central adiposity with menopause will be a major contributor to the increased prevalence of the Metabolic Syndrome with menopause. This is the first prospective study to investigate the 1) effects of menopause and 2) estrogen replacement therapy (ERT) (oral vs. transdermal) on features of the Metabolic Syndrome. We will determine if the increase in central (intraabdominal)fat with menopause is associated with changes in lipids, insulin resistance, adipocytokines, and fibrinolytic/inflammatory markers. We will then determine if these changes can be reversed with transdermal ERT, as compared to oral ERT, which has pharmacologic effects on the liver.
STELARA ®solution for intravenous infusion must be diluted, prepared, and infused by a healthcare professional using aseptic technique. 

  1. Calculate the dose and the number of STELARA ®vials needed based on patient weight (Table 4). Each 26 mL vial of STELARA ®contains 130 mg of ustekinumab. 
  2. Withdraw, and then discard a volume of the 0.9% Sodium Chloride Injection, USP from the 250 mL infusion bag equal to the volume of STELARA ®to be added (discard 26 mL sodium chloride for each vial of STELARA ®needed, for 2 vials- discard 52 mL, for 3 vials- discard 78 mL, 4 vials- discard 104 mL). Alternatively, a 250 mL infusion bag containing 0.45% Sodium Chloride Injection, USP may be used. 
  3. Withdraw 26 mL of STELARA ®from each vial needed and add it to the 250 mL infusion bag. The final volume in the infusion bag should be 250 mL. Gently mix. 
  4. Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration or foreign particles are observed.
  5. Infuse the diluted solution over a period of at least one hour. Once diluted, the infusion should be completely administered within eight hours of the dilution in the infusion bag.
  6. Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer).
  7. Do not infuse STELARA ®concomitantly in the same intravenous line with other agents. 
  8. STELARA ®does not contain preservatives. Each vial is for a single-dose only. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements. 



Storage

If necessary, the diluted infusion solution may be kept at room temperature up to 25°C (77°F) for up to 7 hours. Storage time at room temperature begins once the diluted solution has been prepared. The infusion should be completed within 8 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). Do not freeze. Discard any unused portion of the infusion solution.
Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time. These dosages are for initiation of therapy or for short courses of treatment. The dosage must be carefully adjusted according to the response of the patient and must be reduced as soon as there is an abrupt fall in the white blood cell count. Patients with Hodgkin’s disease usually require 0.2 mg/kg daily, whereas patients with other lymphomas or chronic lymphocytic leukemia usually require only 0.1 mg/kg daily. When lymphocytic infiltration of the bone marrow is present, or when the bone marrow is hypoplastic, the daily dose should not exceed 0.1 mg/kg (about 6 mg for the average patient). Alternate schedules for the treatment of chronic lymphocytic leukemia employing intermittent, biweekly, or once-monthly pulse doses of chlorambucil have been reported. Intermittent schedules of chlorambucil begin with an initial single dose of 0.4 mg/kg. Doses are generally increased by 0.1 mg/kg until control of lymphocytosis or toxicity is observed. Subsequent doses are modified to produce mild hematologic toxicity. It is felt that the response rate of chronic lymphocytic leukemia to the biweekly or once-monthly schedule of chlorambucil administration is similar or better to that previously reported with daily administration and that hematologic toxicity was less than or equal to that encountered in studies using daily chlorambucil.  
  
Radiation and cytotoxic drugs render the bone marrow more vulnerable to damage, and chlorambucil should be used with particular caution within 4 weeks of a full course of radiation therapy or chemotherapy. However, small doses of palliative radiation over isolated foci remote from the bone marrow will not usually depress the neutrophil and platelet count. In these cases chlorambucil may be given in the customary dosage.  
  
It is presently felt that short courses of treatment are safer than continuous maintenance therapy, although both methods have been effective. It must be recognized that continuous therapy may give the appearance of “maintenance” in patients who are actually in remission and have no immediate need for further drug. If maintenance dosage is used, it should not exceed 0.1 mg/kg daily and may well be as low as 0.03 mg/kg daily. A typical maintenance dose is 2 mg to 4 mg daily, or less, depending on the status of the blood counts. It may, therefore, be desirable to withdraw the drug after maximal control has been achieved, since intermittent therapy reinstituted at time of relapse may be as effective as continuous treatment.  


Procedures for proper handling and disposal of anticancer drugs should be used. Several guidelines on this subject have been published.1-4 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
Ischemic stroke stands as the primary cause of long-term disability and mortality among adults worldwide. Animal models of ischemic stroke have significantly contributed to our understanding of its pathological mechanisms and the development of potential treatments. Presently, there are two common methods involving filament (endovascular suture) techniques to induce animal models of cerebral ischemia. However, these methods have inherent limitations, such as reduced blood perfusion to the brain, damage to the external carotid artery system, impaired food and/or water intake, and sensory dysfunction of the face. This article introduces a new method for inducing a rat ischemic stroke model without compromising the cerebral vascular anatomy. In this study, the common carotid artery (CCA) of Sprague-Dawley rats was exposed, and an incision was made. A filament was then inserted through the incision into the internal carotid artery to occlude the middle cerebral artery. After 1.5 h of induced ischemia, the occluding filament was fully removed from both the internal carotid artery and the CCA. The incision in the CCA was subsequently sutured using 11-0 microsurgical sutures under a microscope (magnification 4x). Through the utilization of microsurgical techniques to repair the CCA, this study successfully developed a unique method to induce an ischemic stroke model in rats while preserving the anatomical integrity of cerebral blood vessels.
The San Francisco Department of Public Health, University of California at San Francisco (UCSF), and Project Open Hand (POH), a community based organization in San Francisco which provides meals and groceries to chronically ill clients in the Bay Area, have partnered to conduct a prospective, randomized, wait-list controlled study examining the impact of providing medically appropriate meals and registered dietician (RD) support to patients discharged from Zuckerberg San Francisco General Hospital after acute decompensated heart failure. Before discharge, patients will be randomized to either the intervention or wait list control arm. The intervention consists of the delivery of medically appropriate meals and/or groceries to participants' homes in a tapered manner over five months (the equivalent of three meals a day for 60 days, then the equivalent of two meals a day for 30 days, then the equivalent of one meal a day for 60 days) and monthly nutrition education with a registered dietician (RD). All food and nutritional education are administered by POH staff and RDs. Participants randomized into the wait list control arm will receive the food intervention five months after discharge. The study's primary aim is to examine the impact of nutritional support on the Kansas City Cardiomyopathy Questionnaire scores. In addition, the study aims to examine the impact of nutritional support on healthcare utilization (particularly readmission rates and emergency room utilization), dietary change, medication adherence, and quality of life. The investigators will assess outcomes at baseline while patients are hospitalized, 1 month after discharge, and 5 months after discharge using quantitative surveys. The investigators will call participants at 3 months and 4 months after discharge with a shorter quantitative survey assessing a subset of outcome measures. In addition, the investigators will conduct a qualitative interview near the conclusion of the intervention in a subset of participants to understand perceived impacts of the intervention as well as barriers and facilitators to heart failure care.
The invention discloses a medicine composition for treating infective vaginitis and a preparation method thereof, and relates to the technical field of medicaments of the obstetrics and gynecology department. The medicine composition is prepared from fruits of tree-of-heaven ailanthus, Asiatic pennywort herb, chickweed, roots of long pepper, tropic ageratum herb, shrubalthea bark, colla carapacis trionycis, ammannia auriculata Willd., herba rubiae yunnanensis, tithonia diversifolia A. Gray, oxygraphis glacialis (Fisch. ex DC.) Bunge, helwingia japonica (Thunb.) Dietr., roots of Szechwan-Yunnan sanicle, roots or stems of creeping mallotus, philippine flemingia roots, ipomoea cairica, radix angelicae, dendrobe, maltose, mint oil, glucuronolactone, an amino acid mixture, alpha-pinene, niacin, vitamin C and an antibacterial agent. The medicine composition is prepared according to the theory of traditional Chinese medicine in combination with clinical experience, the selected medicinal materials are reasonable in compatibility and appropriate in proportion, all the ingredients supplement one another and jointly achieve the effects of clearing away heat and toxic materials, dispersing stasis and diminishing swelling, promoting blood circulation and alleviating pain, tonifying Qi and reinforcing deficiency, resisting bacteria and diminishing inflammation, clearing away liver heat and tonifying middle-Jiao and Qi, and the medicine composition can effectively treat infective vaginitis and thoroughly remove the disease and is significant in treatment effect, not likely to cause medicine resistance small in side effect.
FIELD: organic chemistry. SUBSTANCE: products: compounds of the formula (I)where: Rmeans substituted or unsubstituted bivalent aliphatic group with 1-16 carbon atoms where substituents are mono- or poly- and taken from the group involving lower alkyl, aryl and arylalkyl; Ris taken from the group involving the same substituents as R; Ris taken from the group involving substituted and unsubstituted alkyl with 1-10 carbon atoms, aryl, cycloalkyl and heterocycloalkyl with 3-8 carbon atoms where substituents are mono- and poly- and taken from the group involving lower alkyl, cycloalkyl with 3-8 carbon atoms, lower alkenyl, lower alkynyl, nitro, lower alkoxy, lower alkoxycarbonyl, lower alkylphenyl, phenyl, mono- and polyhaloidphenyl, phenoxy, mono- and polyhaloidphenoxy; Rand Rcan be similar or different and mean hydrogen, alkanoyl or alkoxyalkanoyl; Rcan mean the same value as R; Y means oxygen or sulfur; m = 0 or 1; q = 0 or 1 where prefix "alk" means moieties of molecule representing direct chain or branched chain, and term "lower" means 1-6 carbon atoms, and term "alk" without prefixes mean 1-24 carbon atoms, the corresponding tautomeric compounds, pharmaceutically acceptable salts and additive salts, compounds and hydrates of the indicated salts and additive salts. Invention proposes methods of protection from infections caused by Plejmodium sp., Mycobacterium sp. and Pneumocystis racinii, persons infected with these organisms by administration of above indicated compound at effective dose. These compounds decrease infection level when these persons had been infected already. EFFECT: improved method of synthesis, enhanced effectiveness of treatment.
A compilation of outcomes of various antiretroviral therapies would be beneficial when evaluating which strategies are most effective in long-term treatment of HIV-1. Using data from present and recently completed studies, this study will collect information on therapies and their control of HIV infection and maintenance of durable suppression of HIV-1 replication.

No treatment is provided by this study, but patients will continue to receive highly active antiretroviral therapy (HAART) from other studies in which they are coenrolled. Blood and urine collection will occur at study entry and periodically throughout the study. Women may undergo pelvic exams and Pap smears. Portions of blood samples will be stored to evaluate genotypic/phenotypic susceptibility testing. Medical histories, physical exams, and questionnaires will be completed periodically.